Oveporexton is an oral orexin receptor 2 (OX2R)-selective agonist indicated for narcolepsy type 1 in adults, restoring deficient orexin signaling to promote wakefulness and reduce cataplexy and other REM-sleep-related symptoms. NT1 is caused by the loss of orexin neuropeptide signaling, and oveporexton works by selectively activating OX2R to restore this signaling, promoting wakefulness and reducing cataplexy and other REM-sleep-related symptoms.
- Mechanism
- Curator reviewed · 2 references
Oveporexton is an agonist of the orexin receptor 2 (OX2R). Narcolepsy type 1 is associated with the loss of orexin neuropeptide signaling, and oveporexton's mechanism of action in treating it is through OX2R agonism.
- Primary indication
- Oveporexton is indicated for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adult patients.Curator reviewed · 1 structured indication
- Formula / weight
- C23H25F5N2O4S · 520.52 g/mol (avg)
- Code names
- TAK-861
Resolves to
KVMGAIOTUIGROS-AZUAARDMSA-NSMILESCCS(=O)(=O)N[C@@H]1[C@H](CC2=CC=CC(=C2F)C2=CC(F)=CC(F)=C2)N(CC1(F)F)C(=O)C(C)(C)OWhat you can answer from here — as of October 30, 2026
Which drugs share a target with Oveporexton, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account